B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma.
B-cell Non-hodgkin Lymphoma Overview:
B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis.
Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification.
"B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market.
Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report
DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment.
In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies.
In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023.
Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape.
Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others.
B-cell Non-hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market.
Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights
B-cell Non-hodgkin Lymphoma Emerging Drugs
Valemetostat: Daiichi Sankyo
MB-106: Mustang Bio
CB-010: Caribou Biosciences
LP-284: Lantern Pharma
B-cell Non-hodgkin Lymphoma Companies
Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements
B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment
• B-cell Non-hodgkin Lymphoma Assessment by Product Type
• B-cell Non-hodgkin Lymphoma By Stage
• B-cell Non-hodgkin Lymphoma Assessment by Route of Administration
• B-cell Non-hodgkin Lymphoma Assessment by Molecule Type
Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns
4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III)
7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-cell Non-hodgkin Lymphoma Discontinued Products
13. B-cell Non-hodgkin Lymphoma Product Profiles
14. B-cell Non-hodgkin Lymphoma Key Companies
15. B-cell Non-hodgkin Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-cell Non-hodgkin Lymphoma Unmet Needs
18. B-cell Non-hodgkin Lymphoma Future Perspectives
19. B-cell Non-hodgkin Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Rocket Lab Stock Soars Higher as Neutron's Maiden Flight Nears
Rocket Lab Corp. RKLB is currently on the cusp of a transformative milestone with its highly anticipated Neutron rocket approaching its maiden flight in the second half of 2025. To expand beyond its small-launcher Electron and capture the medium-lift payload market, while positioning itself to compete with heavy-lift providers like SpaceX, Rocket Lab launched the Neutron program. This medium-class, reusable vehicle, with a potential payload capacity of approximately 15,000 kg, aims to offer flexible, cost-effective access to space for a wide range of customers, including satellite constellations, government missions, and commercial payloads. To this end, it is imperative to mention that in May 2025 Rocket Lab announced that it will launch its Neutron rocket for the U.S. Air Force Research Laboratory for a Rocket Cargo mission to support point-to-point cargo transportation, establishing a new era of commercial launch capability to advance global defense logistics for the nation. Earlier in February, the company revealed details about the ocean landing platform, a modified barge, for Neutron missions returning to Earth. Customized modification is currently ongoing on this barge, including autonomous ground support equipment to capture and secure the landed Neutron, blast shielding to protect equipment during Neutron landings, and station-keeping thrusters for precise positioning. These announcements implying consistent progress in the Neutron program have bolstered investor confidence, reflected in Rocket Lab's share price performance. While the company's year-to-date price increase has been modest, the past three months have seen a sharper uptick, underscoring growing optimism around Neutron's prospects as new milestones mentioned above are achieved. RKLB's shares gained 40% year to date, while the same soared 103.6% over the past three months. Other Stocks One Should Keep an Eye on The space launch services market has been witnessing solid growth trends driven by surging demand for satellite constellations, increasing government and defense investments, and the growing need for low-cost, reliable access to space to support telecommunications, Earth observation, and national security missions. Therefore, investors interested in this business realm may keep RKLB along with other industry players like Boeing BA and Lockheed Martin LMT in their watchlist, which already enjoy an established footprint in the space launch market. Boeing's products have powered human space exploration for six decades now. The company is the prime contractor for the design, development and production of the core stage, upper stages and flight avionics suite used in NASA's Space Launch System, the only proven deep-space optimized, super-heavy lift rocket built to carry astronauts and cargo farther and faster than any rocket in history. Lockheed Martin is another space stock that has contributed significantly to various space missions with its breakthrough technologies. It is the prime contractor involved in the construction of Orion, the spacecraft that will carry the crew of four astronauts in the Artemis II lunar mission. The Zacks Rundown for RKLB Shares of RKLB have gained 630.8% in the past year compared with the industry 's 50.9% growth. With respect to valuation, the company trades at a premium. RKLB currently trades at a forward 12-month Price/Sales of 22.49X compared with its industry's average of 10.06X. Image Source: Zacks Investment Research The Zacks Consensus Estimates for RKLB's 2025 and 2026 loss have improved over the past 60 days. RKLB stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Rocket Lab Corporation (RKLB): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
2 hours ago
- Globe and Mail
Boeing Stock Set for a Ride as NASA Progresses in Artemis II Program
NASA's Artemis II mission, the first crewed flight in its lunar return program, set to launch in April 2026, has reached critical milestones in recent months, reigniting investor interest in aerospace giant Boeing BA, a key contractor in the Space Launch System (SLS) program. On July 2, 2025, NASA announced on its Facebook page that the Program Specific Engineering Test for the Artemis II core stage had been completed. In early June, the Artemis II team conducted its first mission simulation to rehearse lunar science operations for the upcoming crewed mission. Earlier, in March, the integration of the Artemis II SLS core stage with its solid rocket boosters was successfully completed, which was another key milestone in preparing the rocket for launch. To this end, it is imperative to mention that the SLS rocket, designed to carry astronauts farther into space than ever before, is led by Boeing as the prime contractor for its core stage, upper stage, and avionics systems. The jet giant is currently building the core stages for all future Artemis missions. Thus, for Boeing, Artemis II represents more than just a technological triumph — it's a strategic revenue driver. With the company's Defense, Space & Security segment accounting for nearly 36% of total revenues in 2024, space programs like Artemis are key to Boeing's efforts to gain from a diversified portfolio beyond its struggling commercial aviation business and provide it with a significant financial cushion. With Artemis II on track, NASA's commitment to sustaining the Artemis program through Artemis III and beyond implies recurring revenue potential for Boeing over the long run, given its deep involvement in every SLS flight configuration. As investor interest in space stocks has been gaining increasing traction these days, the continued success of the Artemis mission should strengthen Boeing's positioning in the $500 billion global space economy and offer a promising growth vector for its shares. The potential upside reflected in BA's price target further supports this thesis. Based on short-term price targets provided by 22 analysts, the average Zacks price target for Boeing implies a 6.4% upside from its last closing price. Other Space Stocks Warrant a Look Other stocks, involved in the SLS program and Artemis missions, like Lockheed Martin LMT and L3Harris Technologies Inc. LHX, also stand to benefit from the steady progress of the Artemis II mission. Notably, Lockheed is the prime contractor involved in the construction of Orion, the spacecraft that will carry the crew of four astronauts in the Artemis II mission. In May 2025, LMT achieved a significant milestone in the development of NASA's Orion spacecraft by officially transferring it to NASA's Exploration Ground Systems team, following the completion of the spacecraft's assembly and testing. On the other hand, L3Harris is involved in the Artemis II mission through its Aerojet Rocketdyne business unit, which provides the RS-25 engines that power the SLS core stage. In May 2025, Aerojet Rocketdyne completed installation of all four RS-25 main engines on the core stage of NASA's second SLS exploration rocket, which will be used in the Artemis II mission. The Zacks Rundown for BA Shares of Boeing have risen 22% year to date compared with the industry 's growth of 22.2%. From a valuation standpoint, BA is currently trading at a forward 12-month sales multiple of 1.80X, a roughly 18.9% discount when stacked up with the industry average of 2.22X. The Zacks Consensus Estimate for BA's 2025 and 2026 sales implies a year-over-year uptick of 25.6% and 16.2%, respectively. The same for its earnings per share for 2025 has moved north over the past 60 days, while the same for 2026 has moved south. BA stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report L3Harris Technologies Inc (LHX): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
2 hours ago
- Globe and Mail
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the 'One Big Beautiful Bill Act' through Congress, ready for President Donald Trump's signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone. To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options. UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025. Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit. Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data. Price Performance Comparison – UNH, HUM & CNC Image Source: Zacks Investment Research UnitedHealth's Valuation and Estimates From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report This article originally published on Zacks Investment Research (
